These studies demonstrate that PD-1 blockade potentiates the anti-tumor immune response induced by radiation therapy (RT), including significant effects on non-irradiated or secondary tumors, suggesting that this combination therapy may be a promising therapeutic approach for managing metastatic cancer patients. The gene discussed is PDCD1; the disease is neoplasm.